Objective: We sought to evaluate the efficacy and safety of vildagliptin, a new dipeptidyl peptidase-4 inhibitor, added to metformin during 24 weeks of treatment in patients with type 2 diabetes.
Am J Health Syst Pharm. 2007;64(12):1265-1273.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback